supp.fit

Palmitoylethanolamide: study protocols

6 study groups say how much Palmitoylethanolamide participants took a day. These are the doses the studies gave. They are not a recommendation.

Palmitoylethanolamide: what the research found →

Dose per serving from products

60 products in our catalogue print how much Palmitoylethanolamide a serving holds.

Most common: 500 mg to 1 g, 45% of 60 products.

Dose per servingProducts
25 mg or less
1
25 mg to 50 mg
5
50 mg to 100 mg
5
100 mg to 250 mg
6
250 mg to 500 mg
16
500 mg to 1 g
27

Dose per serving from research

6 study groups in 4 studies say how much Palmitoylethanolamide participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 83% of 6 study groups.

Daily doseStudy groups
500 mg to 1 g
5
1 g to 2.5 g
1

Commonly used together

4 of 6 study groups took Palmitoylethanolamide with something else, but nothing that 3 or more different studies gave.

6 study groups

Study
A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
2022 · Active treatment group · Men and women aged 32–75 with type 1 or type 2 diabetes and diabetic-related peripheral neuropathy with neuropathic pain
600 mg8 weeks33
The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial
2023 · Levagen+ (PEA) group · Adults aged 18–65 years without a stated illness, recruited as otherwise healthy adults
600 mg12 weeks—
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial
2022 · Intervention group · Adults aged 18–80 with post-COVID-19 anosmia or hyposmia persisting at least 180 days
700 mg90 days130
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
2023 · Combined therapy (um-PEA–LUT: once daily + olfactory training) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19
700 mg90 days76
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
2023 · um-PEA–LUT alone (once daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19
700 mg90 days48
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
2023 · um-PEA–LUT alone (twice daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19
1.4 g90 days40